Open Access

The case for early LDL-c lowering in patients at increased CV risk: when should we start?

Topic: Pharmacology and Pharmacotherapy
Sponsored by PACE-CME - Supported by unrestricted educational grants from Amgen and NewAmsterdam/Menarini

Congress Presentation

About the speaker

Professor Pasquale Perrone-Filardi

Federico II University Hospital, Napoly (Italy)
10 presentations
1 follower

4 more presentations in this session

The remaining challenges in lowering LDL-c in patients at increased CV risk

Speaker: Professor K. Ray (London, GB)

Thumbnail

Reaching LDL-c targets in patients at high CV risk: how well are we doing?

Speaker: Doctor J. Brandts (Aachen, DE)

Thumbnail

Novel oral LDL-c lowering therapies on the horizon: CETP inhibition

Speaker: Professor U. Laufs (Leipzig, DE)

Thumbnail

Discussion

Speaker: Professor K. Ray (London, GB)

Thumbnail

Access the full session

Clinical choices in managing LDL-c: where do novel therapies fit in?

Speakers: Professor P. Perrone-Filardi, Professor K. Ray, Doctor J. Brandts, Professor U. Laufs, Professor K. Ray
Thumbnail

About the event

Image

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations